Axa S.A. Has $26.04 Million Holdings in Penumbra, Inc. (NYSE:PEN)

Axa S.A. lessened its stake in shares of Penumbra, Inc. (NYSE:PEN) by 1.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 109,641 shares of the company’s stock after selling 1,478 shares during the quarter. Axa S.A.’s holdings in Penumbra were worth $26,038,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. China Universal Asset Management Co. Ltd. bought a new position in shares of Penumbra during the fourth quarter valued at $573,000. E. Ohman J or Asset Management AB lifted its holdings in Penumbra by 10.4% during the 4th quarter. E. Ohman J or Asset Management AB now owns 21,312 shares of the company’s stock valued at $5,061,000 after purchasing an additional 2,000 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Penumbra by 1.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 271,574 shares of the company’s stock valued at $64,493,000 after buying an additional 3,807 shares in the last quarter. Washington Capital Management Inc. bought a new stake in Penumbra during the fourth quarter worth about $226,000. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Penumbra by 39.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 299,397 shares of the company’s stock worth $71,831,000 after buying an additional 85,284 shares in the last quarter. Institutional investors and hedge funds own 88.88% of the company’s stock.

Penumbra Stock Performance

Shares of Penumbra stock opened at $295.97 on Monday. The firm has a fifty day moving average of $277.12 and a two-hundred day moving average of $258.33. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. The stock has a market capitalization of $11.46 billion, a price-to-earnings ratio of 870.50, a PEG ratio of 2.83 and a beta of 0.56. Penumbra, Inc. has a 52 week low of $148.00 and a 52 week high of $310.00.

Penumbra (NYSE:PEN) last released its quarterly earnings data on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.17. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The business had revenue of $324.14 million during the quarter, compared to the consensus estimate of $315.72 million. During the same quarter in the prior year, the company posted $0.41 earnings per share. The firm’s revenue was up 16.3% on a year-over-year basis. As a group, equities research analysts predict that Penumbra, Inc. will post 3.67 EPS for the current year.

Insider Buying and Selling

In related news, CAO Lambert Shiu sold 501 shares of the firm’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $282.88, for a total transaction of $141,722.88. Following the sale, the chief accounting officer now owns 32,969 shares of the company’s stock, valued at approximately $9,326,270.72. This trade represents a 1.50 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Johanna Roberts sold 600 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $287.43, for a total value of $172,458.00. Following the completion of the transaction, the executive vice president now directly owns 66,539 shares of the company’s stock, valued at approximately $19,125,304.77. The trade was a 0.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 140,446 shares of company stock valued at $39,543,953 in the last 90 days. 5.00% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

PEN has been the topic of several recent analyst reports. Canaccord Genuity Group boosted their target price on Penumbra from $323.00 to $340.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Robert W. Baird boosted their price objective on Penumbra from $316.00 to $325.00 and gave the stock an “outperform” rating in a research note on Thursday, April 24th. BTIG Research restated a “buy” rating on shares of Penumbra in a research note on Thursday, April 24th. Truist Financial upped their price target on shares of Penumbra from $315.00 to $330.00 and gave the stock a “buy” rating in a research report on Thursday, April 24th. Finally, Piper Sandler restated an “overweight” rating and issued a $330.00 price objective (up previously from $250.00) on shares of Penumbra in a research report on Wednesday, February 19th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $302.40.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.